Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00271180 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

Study acronym: PPR
StatusRecruiting
PhaseNot specified
SponsorMedtronic
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 57 record versions are listed below. See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 320 → 333 locationsv57
  2. Study sites: 318 to 320v56
  3. Study sites: 315 to 318v55
  4. Study sites: 314 to 315v54
  5. Study sites: 312 to 314v53
Show 45 earlier versionsHide 45 earlier versions
  1. Study sites revised (312)v52 See this version in full on ClinicalTrials.gov ↗
  2. Study sites revised (312)v51 See this version in full on ClinicalTrials.gov ↗
  3. Study sites: 309 to 312v50
  4. Study sites: 307 to 309v49
  5. Study sites: 303 to 307v48
  6. Study sites: 301 to 303v47
  7. Study sites: 296 to 301v46
  8. Study sites: 291 to 296v45
  9. Study sites: 281 to 291v44
  10. Study sites: 276 to 281v43
  11. Study sites: 273 to 276v42
  12. Study sites: 271 to 273v41
  13. Study sites revised (271)v40 See this version in full on ClinicalTrials.gov ↗
  14. Study sites: 269 to 271v39
  15. Study sites: 268 to 269v38
  16. Study sites: 257 to 268v37
  17. Study sites revised (257)v36 See this version in full on ClinicalTrials.gov ↗
  18. Study sites: 256 to 257v35
  19. Study sites: 253 to 256v34
  20. Study sites: 244 to 253v33
  21. Study sites: 240 to 244v32
  22. Study sites: 241 to 240v31
  23. Study sites: 234 to 241v30
  24. Study sites: 232 to 234v29
  25. Study sites: 230 to 232v28
  26. Study sites: 226 to 230v27
  27. Study sites: 224 to 226v26
  28. Study sites: 225 to 224v25
  29. Study sites: 222 to 225v24
  30. Study sites: 220 to 222v23
  31. Study sites: 218 to 220v22
  32. Study sites: 217 to 218v21
  33. Study sites: 218 to 217v20
  34. Study sites: 212 to 218v19
  35. Enrollment target: 13000 to 20000 Primary and study completion dates: Dec 2024 to Dec 2040 · Study sites: 221 to 212v18 Show 2 more changesShow less
    • Primary and study completion dates: Dec 2024 to Dec 2040
    • Study sites: 221 to 212
  36. Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure to Medtronic Enrollment target: 15000 to 13000 · Study sites: 15 to 221v17 Show 2 more changesShow less
    • Enrollment target: 15000 to 13000
    • Study sites: 15 to 221
  37. Study sites: 13 to 15 Primary and study completion dates: Dec 2024 · Eligibility criteria shortened, about 31 words · Study description expanded, about 20 words · 1 morev16 Show 4 more changesShow less
    • Primary and study completion dates: Dec 2024
    • Eligibility criteria shortened, about 31 words
    • Study description expanded, about 20 words
    • Study title expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  38. Re-verified, no change to tracked fieldsv15
  39. Study sites: 42 to 13v14
  40. Primary endpoint revised Study sites: 107 to 42 · Eligibility criteria revisedv13 Show 2 more changesShow less
    • Study sites: 107 to 42
    • Eligibility criteria revised

    See this version in full on ClinicalTrials.gov ↗

  41. Re-verified, no change to tracked fieldsv12
  42. Study sites: 78 to 107 Study title expanded, about 2 wordsv11 Show 1 more changeShow less
    • Study title expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  43. Study sites: 44 to 78 Eligibility criteria expanded, about 70 wordsv10 Show 1 more changeShow less
    • Eligibility criteria expanded, about 70 words

    See this version in full on ClinicalTrials.gov ↗

  44. Study sites: 30 to 44 Eligibility criteria expanded, about 86 wordsv9 Show 1 more changeShow less
    • Eligibility criteria expanded, about 86 words

    See this version in full on ClinicalTrials.gov ↗

  45. Re-verified, no change to tracked fieldsv8
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Medtronic
16 trials monitored
See all monitored trials
Heart Failure
1,871 trials monitored
See 100 trials at risk
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.
Trial Details
NCT Number NCT00271180
Lead Sponsor Medtronic
Conditions Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
Enrollment 20,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov